Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners